

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
26 June 2025 (26.06.2025)



(10) International Publication Number
WO 2025/137213 A1

(51) International Patent Classification:
C12N 9/26 (2006.01) A61K 38/00 (2006.01)

(21) International Application Number:
PCT/US2024/060936

(22) International Filing Date:
19 December 2024 (19.12.2024)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/612,862 20 December 2023 (20.12.2023) US

(71) Applicant: **DENALI THERAPEUTICS INC.** [US/US];
161 Oyster Point Blvd., South San Francisco, California
94080 (US).

(72) Inventors: **KARIOLIS, Mihalis S.**; 161 Oyster Point
Blvd., South San Francisco, California 94080 (US).
LENSER, Melina; 161 Oyster Point Blvd., South San
Francisco, California 94080 (US). **MAHON, Cathal S.**;
161 Oyster Point Blvd., South San Francisco, California
94080 (US). **NGO, Hanh Giai**; 161 Oyster Point Blvd.,
South San Francisco, California 94080 (US). **RAJENDRA,**
Yashas; 161 Oyster Point Blvd., South San Francisco, Cal-
ifornia 94080 (US). **TYAGI, Shrishti**; 161 Oyster Point

Blvd., South San Francisco, California 94080 (US). **YUAN,**
Tianao; 161 Oyster Point Blvd., South San Francisco, Cal-
ifornia 94080 (US).

(74) Agent: **KRUEGER, Katherine A.D.** et al.; Viksnins Har-
ris Pady's Malen LLP, 7900 International Drive, Suite 410,
Bloomington, Minnesota 55425 (US).


(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,
SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,
RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,
DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,

(54) Title: FUSION PROTEINS COMPRISING ACID ALPHA-GLUCOSIDASE ENZYMES AND METHODS THEREOF

(57) Abstract: Provided herein are proteins, which are capable of being
transported across the blood- brain barrier (BBB) and comprise an acid
alpha-glucosidase (GAA) enzyme-Fc fusion polypeptide. Certain embodi-
ments also provide methods of using such proteins to treat Pompe disease.

FIGURES 1A-1B



WO 2025/137213 A1

[Continued on next page]

LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,
SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*